Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

299 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-08-27

Study Completion Date

2021-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

International, multicenter, epidemiological study to demonstrate the correlation and predictive value of lyso-Gb1 concentration with the clinical severity of naïve, initially non-ERT/SRT Gaucher disease type 1 and during the study ERT/SRT-newly started Gaucher type 1 patients and to correlate lyso-Gb1 concentration with the clinical improvement of ERT or SRT treated Gaucher type 1 and the clinical course of non-treated patients based on GD-DS3

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis

NCT04273269

GM1 Gangliosidosis

TERMINATED PHASE1/PHASE2

Biomarkers Related to Bone in Pediatric Gaucher Disease

NCT06116071

Gaucher Disease Bone Diseases

RECRUITING

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

NCT00358943

Gaucher Disease Cerebroside Lipidosis Syndrome Glucocerebrosidase Deficiency Disease +1 more

RECRUITING

A Gene Therapy Study in Patients With Gaucher Disease Type 1

NCT05324943

Gaucher Disease, Type 1

COMPLETED PHASE1

A Screening Study Evaluating Disease Status of Gaucher Type I Patients

NCT00795197

Gaucher Disease, Type 1

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Gaucher disease is an autosomal recessive inherited lysosomal storage disorder. The disease is caused by the hereditary deficiency of the glucocerebrosidase, a lysosomal enzyme that breaks down glucocerebroside into glucose and ceramide.

To date a definitive diagnosis of Gaucher's disease can only be made applying biochemical testing measuring the reduced enzymatic activity of the beta-glucosidase together with genetic confirmation. Since numerous different mutations may be the cause of a particular lysosomal storage disease the sequencing of the entire beta-glucosidase gene is applied in Gaucher's disease in order to confirm the genetic diagnosis.

The use of primary storage molecules as biomarker was assessed for glucosylceramide (Gb1) in plasma of Gaucher's disease patients and compared to the level of Gb1 in healthy individuals.

In order to establish a sensitive and specific biomarker for GD, we compared mass spectra of the plasma of healthy controls and GD patients using HPLC and tandem mass spectrometry. Mass spectra that differed most between patients and controls were analysed in more detail. The resulting biomarker, which was patented in June 2011 (PCT/EP2012/002409), was lyso - Gb1. We identified this compound as a reliable, sensitive and specific biomarker for GD in a cohort of GD patients. Furthermore, in a pilot study we evaluated whether lyso-Gb1 is related to the specific genotypes and is reliable for long-term monitoring of the efficiency of therapy.

The aim this study is therefore to investigate lyso-Gb1 as a long-term prognostic marker in naïve, non-ERT/SRT GD type 1 patients by monitoring over the course of 36 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lysosomal Storage Diseases Gaucher Disease Sphingolipidoses

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants diagnosed with Gaucher disease

Participants with genetically confirmed diagnosis of Gaucher disease type 1 older than 6 months old

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients aged 6 months or older
* Patients with genetically confirmed diagnosis of Gaucher disease type 1
* No prior treatment with enzyme replacement therapy or substrate reduction therapy ro no traetment for more than 24 months
* Signed informed consent by parents/legal guardian and patient

Exclusion Criteria

* Male or female patients being younger than 6 months
* Patients without genetically confirmed diagnosis of Gaucher disease type 1
* Gaucher disease 2 or 3
* Patient is currently undergoing enzyme replacement therapy or substrate reduction therapy
* Missing signed informed consent

Minimum Eligible Age

6 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No